Clinical trials: Hypertension, Pulmonary Arterial
Hypertension, Pulmonary
Evaluate the Efficacy, Safety and Pharmacokinetics of GSK1325760A in the Treatment of Pulmonary Arterial Hypertension
The primary objective of this study is to evaluate the effect of GSK1325760A on improvement in exercise capacity in subjects with pulmonary arterial hypertension (PAH).
- Trial name
- NCT00540436
- Testing
- GSK1325760A
- Where
- 15 sites in Japan
- Volunteers
- 25 people
- Sponsor
- GlaxoSmithKline
Hypertension, Pulmonary
Rapid Switch From Flolan to Remodulin in the Outpatient Clinic
The purpose of this 8-week study is to compare the effects of switching from therapy with epoprostenol or Flolan to IV Remodulin.
- Trial name
- NCT00643604
- Testing
- treprostinil sodium
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- United Therapeutics
Pulmonary Arterial Hypertension
A Study of Selexipag Assessing Right Ventricular Remodeling in Pulmonary Arterial Hypertension by Cardiac Magnetic Resonance Imaging
The purpose of the study is to assess the effects of selexipag on right ventricular (RV) function in participants with Pulmonary arterial hypertension (PAH).
- Trial name
- RESTORE (NCT04435782)
- Testing
- JNJ-67896049
- Where
- 35 sites in United States, Argentina and 13 more
- Volunteers
- 9 people
- Sponsor
- Actelion
Pulmonary Arterial Hypertension
A Long-Term, Open-Label Study to Evaluate the Safety of Sitaxsentan Sodium Treatment in Patients With Pulmonary Arterial Hypertension
This is a multi-center, open-label study of sitaxsentan sodium 100 mg taken orally once daily by subjects with PAH until sitaxsentan, in a particular country or region, is commercially available for the treatment of PAH or the…
- Trial name
- STRIDE-3 (NCT00811018)
- Testing
- Sitaxsentan
- Where
- 91 sites in United States, Argentina and 14 more
- Volunteers
- 1,192 people
- Sponsor
- Pfizer
Pulmonary Arterial Hypertension
Anastrozole in Patients With Pulmonary Arterial Hypertension
The main purpose of this clinical trial is to study the safety and efficacy of anastrozole in adults diagnosed with pulmonary arterial hypertension (PAH). The study will evaluate how well the drug is tolerated.
- Trial name
- AIPH (NCT01545336)
- Testing
- Anastrozole
- Where
- 3 sites in United States
- Volunteers
- 18 people
- Sponsor
- University of Pennsylvania
Pulmonary Hypertension
The "VISION" Trial: Ventavis Inhalation With Sildenafil to Improve and Optimize Pulmonary Arterial Hypertension
The purpose of this multi-center international trial is to evaluate the safety and effectiveness of adding iloprost or placebo (an inactive substance that contains no active study drug) to sildenafil therapy for pulmonary…
- Trial name
- VISION (NCT00302211)
- Testing
- Inhaled Iloprost (5 μg), Sildenafil, Bosentan
- Volunteers
- 67 people
- Sponsor
- Actelion
Pulmonary Arterial Hypertension
Clinical Study of Pulsed, Inhaled Nitric Oxide Versus Placebo in Symptomatic Subjects With PAH
Phase 3, placebo controlled, double-blind, randomized clinical study to determine safety, tolerability, and efficacy of pulsed, inhaled nitric oxide (iNO) versus placebo in symptomatic subjects with pulmonary arterial…
- Trial name
- INOvation-1 (NCT02725372)
- Testing
- Inhaled Nitric Oxide 75 mcg/kg IBW/hr
- Where
- 109 sites in United States, Australia and 16 more
- Volunteers
- 207 people
- Sponsor
- Bellerophon Pulse Technologies
Pulmonary Arterial Hypertension, Iron Deficiency
IV Iron Replacement for Iron Deficiency in Idiopathic Pulmonary Arterial Hypertension (IPAH) Patients
This study will establish whether intravenous iron replacement has clinical benefit in idiopathic pulmonary arterial hypertension.
- Trial name
- NCT01447628
- Testing
- Saline, Ferinject or CosmoFer
- Where
- 5 sites in China, Germany and 1 more
- Volunteers
- 56 people
- Sponsor
- Imperial College London
Pulmonary Arterial Hypertension
Pilot Chart Review Study Of Sitaxentan Sodium (Thelin) In Patients With Pulmonary Arterial Hypertension (PAH)
The objectives of this study are to develop research methods and corresponding materials for a study of the effectiveness of sitaxentan sodium (Thelin) in "real-world" settings; to pilot test these methods at three study centers…
- Trial name
- NCT01445873
- Testing
- Sitaxentan sodium
- Volunteers
- 36 people
- Sponsor
- Pfizer
Primary Pulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary Hypertension
Effects of Riociguat on RIght VEntricular Size and Function in PAH and CTEPH
This is an open-label, single-armed, prospective single-centre clinical study to evaluate the effect of riociguat on right heart size and function in patients with manifest PAH and CTEPH.
- Trial name
- RIVERII (NCT04954742)
- Testing
- Riociguat
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Heidelberg University
Pulmonary Arterial Hypertension
A Study to Assess Whether Macitentan Delays Disease Progression in Children With Pulmonary Arterial Hypertension (PAH)
This is a prospective, multicenter, open-label, randomized, controlled, parallel Phase 3 study with an open-label single-arm extension period to evaluate pharmacokinetics (PK), safety and efficacy of macitentan in children with…
- Trial name
- TOMORROW (NCT02932410)
- Testing
- Macitentan, Standard-of-care
- Where
- 85 sites in United States, Australia and 21 more
- Volunteers
- 165 people
- Sponsor
- Actelion
Pulmonary Hypertension
Evaluate Effect of Optison on Pulmonary Artery Systolic Pressure (PASP) and Pulmonary Vascular Resistance (PVR).
The design of this study is to conduct a comprehensive safety evaluation of the pulmonary hemodynamic effects of Optison. The study is being conducted in subjects referred for cardiac catheterization for clinical reasons.
- Trial name
- NCT00878878
- Testing
- Optison (Perflutren Protein-Type A Microspheres Injectable Suspension), Dextrose
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- GE Healthcare
Primary Pulmonary Hypertension
Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil
The primary objective of this study is to evaluate the long-term safety and tolerability of LIQ861, a dry powder formulation of treprostinil, in patients with Pulmonary Arterial Hypertension (PAH).
- Trial name
- INSPIRE (NCT03399604)
- Testing
- LIQ861 Inhaled Treprostinil
- Where
- 38 sites in United States
- Volunteers
- 121 people
- Sponsor
- Liquidia Technologies, Inc.
Pulmonary Hypertension, Sickle Cell Disease
Macitentan in Pulmonary Hypertension of Sickle Cell Disease
This is a pilot study to assess the safety and efficacy of macitentan in patients with pulmonary hypertension of sickle cell disease. This study will enroll approximately 10 subjects.
- Trial name
- MENSCH (NCT02651272)
- Testing
- macitentan
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Boston University
Pulmonary Arterial Hypertension
Effects of Two Dosing Regimens of Bosentan in Children With Pulmonary Arterial Hypertension
The primary objective of AC-052-373 was to assess the pharmacokinetic (PK) profile of two dosing regimens of the pediatric formulation of bosentan in children with pulmonary arterial hypertension (PAH) <12 years of age.
- Trial name
- FUTURE 3 (NCT01223352)
- Testing
- bosentan
- Volunteers
- 64 people
- Sponsor
- Actelion
Pulmonary Arterial Hypertension
A Study of Macitentan in Japanese Pediatric Participants With Pulmonary Arterial Hypertension
The purpose of this study is to evaluate the effect of macitentan on hemodynamic measures at Week 24 in pediatric populations.
- Trial name
- NCT05167825
- Testing
- Macitentan
- Where
- 11 sites in Japan
- Volunteers
- 7 people
- Sponsor
- Janssen Pharmaceutical K.K.
Pulmonary Arterial Hypertension
Clinical Study of Macitentan in Patients With Pulmonary Arterial Hypertension to Psychometrically Validate the PAH-SYMPACT Instrument
SYMPHONY is prospective, multi-center, open-label, single-arm, Phase 3b psychometric validation study of the PAH-SYMPACT, a new quality of life questionnaire for patients with pulmonary arterial hypertension.
- Trial name
- NCT01841762
- Testing
- Macitentan
- Where
- 81 sites in United States
- Volunteers
- 284 people
- Sponsor
- Actelion
Pulmonary Arterial Hypertension
Extension Study of Efficacy and Safety of LTP001 in Pulmonary Arterial Hypertension Participants
The purpose of this study was to measure the long-term safety and efficacy profile of LTP001 in participants with pulmonary arterial hypertension (PAH).
- Trial name
- NCT05764265
- Testing
- LTP001
- Where
- 12 sites in United States, Argentina and 5 more
- Volunteers
- 31 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Arterial Hypertension
Study to Assess the Tolerability and the Safety of the Transition From Inhaled Treprostinil to Oral Selexipag in Patients With Pulmonary Arterial Hypertension
This study enrolls patients with pulmonary arterial hypertension (PAH) treated with inhaled treprostinil. During the study, the treatment with inhaled treprostinil will be tapered off and simultaneously replaced with an oral…
- Trial name
- TRANSIT-1 (NCT02471183)
- Testing
- Selexipag
- Where
- 15 sites in United States
- Volunteers
- 34 people
- Sponsor
- Actelion
Pulmonary Hypertension
FREEDOM-C: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor for the Treatment of Pulmonary Arterial Hypertension (PAH)
This study was an international, multi-center, randomized, double-blind, placebo-controlled study in subjects with PAH who were currently receiving approved therapy for their PAH (i.e., endothelin receptor antagonist and/or…
- Trial name
- NCT00325442
- Testing
- Oral treprostinil (UT-15C) sustained release tablets
- Where
- 72 sites in United States, Australia and 12 more
- Volunteers
- 354 people
- Sponsor
- United Therapeutics